Belzutifan plus cabozantinib maintained durable antitumor activity in advanced clear cell renal cell carcinoma, per phase 3 ...

The EPIC-B trial demonstrates the efficacy of cemiplimab monotherapy as a treatment for locally advanced or metastatic penile cancer (la/mPC). The trial met its primary endpoint, with a clinical ...

Cisplatin-based neoadjuvant chemotherapy (NAC) followed by radical cystectomy (RC) or chemoradiotherapy (CRT) is the standard of care for patients with muscle invasive bladder cancer (MIBC). Mutations ...

Q3 2025 Earnings Call Transcript February 13, 2025 Operator: And good day. Thank you for standing by. Welcome to VistaGen ...

Schrödinger faces financial losses amid investment in experimental drugs. Key 2025 trial results will reveal its future ...

Casas, MD, discusses a systematic review of recent trials examining objective response rate and adverse events of antibody drug conjugate (ADC) combinations in advanced urothelial cancer.

If AV-1 shows promising results in this clinical trial, researchers may pursue further clinical evaluations of its safety and ...

Swedish biotech company Gesynta Pharma AB has secured $27 million in a Series B financing round led by Innovestor Life Science in Finland.

Vistagen Therapeutics' Q3 2025 earnings reveal progress on Phase 3 trials for social anxiety drug fasedienol, innovative therapies, and strong ...

Phase I clinical trials are the first step in testing a new treatment or combination of treatments. These trials often ...

From a study that analyzed brain images of more than 2,500 people with Parkinson's disease in 20 different countries, ...

Insilico Medicine ( "Insilico") , a clinical stage generative artificial intelligence (AI)-driven biotechnology company today announced a set of preclinical drug discovery benchmarks from the 22 ...